Sign in

CIK 0001826457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Monte Rosa Therapeutics, Inc.

Sign in to watch
Ticker
GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 617-949-2643
Business address
321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
Former names
Monte Rosa Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$137
in 1 filing

Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Bowen Matthew −$137 Principal Accounting Officer sold <1% of stake
Date Insider Transaction Shares Price Value Owned after
2021-06-28 Bolzon Bradley J PhD Director Conversion · Series A convertible preferred stock −20,004,280 0
2021-06-28 Bolzon Bradley J PhD Director Conversion · Series B convertible preferred stock −3,000,000 0
2021-06-28 Bolzon Bradley J PhD Director Conversion · Series B convertible preferred stock −4,150,000 0
2021-06-28 Bolzon Bradley J PhD Director Conversion · Series C convertible preferred stock −2,699,328 0
2021-06-28 Versant Venture Capital VI, L.P. 10% owner Conversion +6,515,869 6,799,115
2021-06-28 Versant Venture Capital VI, L.P. 10% owner Conversion +1,940,043 1,940,043
2021-06-28 Versant Venture Capital VI, L.P. 10% owner Purchase +157,895 $19.00 $3.0M 2,097,938
2021-06-28 Versant Venture Capital VI, L.P. 10% owner Conversion · Series A convertible preferred stock −20,004,280 0
2021-06-28 Versant Venture Capital VI, L.P. 10% owner Conversion · Series B convertible preferred stock −3,000,000 0
2021-06-28 Versant Venture Capital VI, L.P. 10% owner Conversion · Series B convertible preferred stock −4,150,000 0
2021-06-28 Versant Venture Capital VI, L.P. 10% owner Conversion · Series C convertible preferred stock −2,699,328 0
2021-06-23 Behbahani Ali Director Grant or award · Stock Option (Right to Buy) +47,132 47,132
2021-06-23 Wallace Owen B. Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +113,298 113,298
2021-06-23 Tamboli Ajim Chief Financial Officer Grant or award · Stock Option (Right to Buy) +56,649 56,649
2021-06-23 Leo Chandra P. Director Grant or award · Stock Option (Right to Buy) +47,132 47,132
2021-06-23 SCHIFF ANDREW N Director Grant or award · Stock Option (Right to Buy) +47,132 47,132
2021-06-23 Blackwell Kimberly Director Grant or award · Stock Option (Right to Buy) +47,132 47,132
2021-06-23 Janku Filip Chief Medical Officer Grant or award · Stock Option (Right to Buy) +387,069 387,069
2021-06-23 Bolzon Bradley J PhD Director Grant or award · Stock Option (Right to Buy) +47,132 47,132
2021-06-23 Siu Christine Director Grant or award · Stock Option (Right to Buy) +47,132 47,132

Page 15 of 16 · 310 trades